Your browser doesn't support javascript.
loading
Open-Label Interventional Study in Healthy Volunteers to Evaluate NO-Mediated Vasodilation by Dermal Allyl Isothiocyanate Challenge and Whole-Body Heat Stress.
van Ruissen, Marella C E; van Kraaij, Sebastiaan J W; Gal, Pim; Bakker, Wouter A; Hijma, Hemme J; Groeneveld, Geert Jan; de Kam, Marieke L; Burggraaf, Jacobus; Moerland, Matthijs.
Afiliación
  • van Ruissen MCE; Center for Human Drug Research, Leiden, The Netherlands.
  • van Kraaij SJW; Leiden University Medical Center, Leiden, The Netherlands.
  • Gal P; Center for Human Drug Research, Leiden, The Netherlands.
  • Bakker WA; Leiden University Medical Center, Leiden, The Netherlands.
  • Hijma HJ; Center for Human Drug Research, Leiden, The Netherlands.
  • Groeneveld GJ; Leiden University Medical Center, Leiden, The Netherlands.
  • de Kam ML; Center for Human Drug Research, Leiden, The Netherlands.
  • Burggraaf J; Leiden University Medical Center, Leiden, The Netherlands.
  • Moerland M; Center for Human Drug Research, Leiden, The Netherlands.
J Exp Pharmacol ; 16: 285-294, 2024.
Article en En | MEDLINE | ID: mdl-39308849
ABSTRACT
Dermal allyl isothiocyanate (AITC) administration and whole-body heat stress (WBHS) are two challenge models that are used to evaluate physiological mechanisms of vasodilation and pharmacological activity in humans. Their exact vasodilatory mechanisms in humans are not fully elucidated but are likely to be nitric oxide (NO)-mediated. This study aimed to evaluate whether there is overlap in the vasodilatory pathways of dermal AITC application and WBHS by combining the challenges. In this open-label interventional study, healthy volunteers underwent dermal administration of AITC twice under basal conditions and during WBHS. Dermal blood flow (DBF) was non-invasively measured using laser speckle contrast imaging four times, once in each of the following situations baseline, WBHS only, AITC only, and WBHS combined with AITC. A total of 12 male volunteers, aged 18-61 years, participated in the study. Compared to baseline, following AITC application, their DBF increased by 63.43 AU (baseline 32.55, 95% CI [17.78, 47.31] AU, AITC only 95.97, 95% CI [81.21, 110.7] AU, p < 0.0001). During WBHS, the increase in DBF after AITC was 42.76 AU (WBHS only 87.25, 95% CI [72.49, 102.0] AU, WBHS+AITC 130.0, 95% CI [115.2, 144.8] AU, p < 0.0001). The combination of WBHS and AITC resulted in a lower DBF than the sum of the DBF responses to AITC and WBHS when applied separately (ED 20.67, 95% CI [-3.532, 44.88], p = 0.0916). This might point towards the presence of an interaction in the vasodilatory mechanism of AITC application and WBHS, possibly indicating overlap in their NOS-driven vasodilatory pathways.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: J Exp Pharmacol Año: 2024 Tipo del documento: Article País de afiliación: Países Bajos Pais de publicación: Nueva Zelanda

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: J Exp Pharmacol Año: 2024 Tipo del documento: Article País de afiliación: Países Bajos Pais de publicación: Nueva Zelanda